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Abstract
Background: Histamine is an established growth factor for gastrointestinal malignancies. The effect of histamine is largely
determined locally by the histamine receptor expression pattern. Histamine receptor H4 (HRH4), the newest member of the
histamine receptor family, is positively expressed on the epithelium of the gastrointestinal tract, and its function remains to
be elucidated. Previously, we reported the decreased expression of HRH4 in colorectal cancers and revealed its correlation
with tumor proliferation. In the current study, we aimed to investigate the abnormalities of HRH4 gene in gastric carcinomas
(GCs).
Methodology/Principal Findings: We analyzed H4R expression in collected GC samples by quantitative PCR, Western blot
analysis, and immunostaining. Our results showed that the protein and mRNA levels of HRH4 were reduced in some GC
samples, especially in advanced GC samples. Copy number decrease of HRH4 gene was observed (17.6%, 23 out of 131),
which was closely correlated with the attenuated expression of H4R. In vitro studies, using gastric cancer cell lines, showed
that the alteration of HRH4 expression on gastric cancer cells influences tumor growth upon exposure to histamine.
Conclusions/Significance: We show for the first time that deletion of HRH4 gene is present in GC cases and is closely
correlated with attenuated gene expression. Down-regulation of HRH4 in gastric carcinomas plays a role in histamine-
mediated growth control of GC cells.
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Introduction
Histamine is a ubiquitous chemical messenger that has been
demonstrated to be involved in cell proliferation, embryonic
development, and tumor growth. These various biological effects
are mediated through the activation of specific histamine receptors
(H1, H2, H3 and H4) that differ in their tissue expression patterns
and functions [1]. Through these pharmacologically distinct
receptors, histamine may act as an autocrine or paracrine growth
factor that increases proliferation rate in malignant tissues [2,3,4].
Among the histamine receptor family, histamine receptor H1
(HRH1) and histamine receptor H2 (HRH2) have long been
considered to be involved in histamine-mediated gastrointestinal
cancer growth [5,6,7,8]. Antagonists of HRH1 or HRH2 have
been reported to be involved in the growth control of several types
of tumors [1,6,9] and their inclusion in human therapy has been
proposed.
The histamine receptor H4 (HRH4) is the most recently
discovered histamine receptor and has a distinct pharmacological
profile [10]. It plays a role in immunological and inflammatory
processes and is predominantly expressed on hematopoietic and
immune cells [11]. Quite recently, accumulated evidence indicates
that HRH4 also plays a role in cell proliferation, both in normal
and malignant cells, including hematopoietic progenitor cells [12],
breast cancer cells [13], and pancreatic carcinoma cells [14].
HRH4 is positively expressed in the whole gastrointestinal tract
[15], although its function remains unclear. Abnormalities of H4R
in colorectal malignancies [16,17] have been reported and the role
of HRH4 has been postulated in the proliferation of colon
carcinoma cells [17,18]. Until now, however, little is known
whether there are any abnormalities of HRH4 gene in gastric
carcinomas (GCs).
GC is currently the most common cancer in China, responsible
for about 300,000 deaths per year. Both genetic and environmen-
tal factors contribute to disease etiology. Studies using array
comparative genomic hybridization (aCGH) have suggested that
DNA deletions at chromosome position 18q11, also the chromo-
some locus of HRH4, are frequent in gastrointestinal malignancies
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31207[19,20,21,22]. Here we aimed to examine the mRNA expression
levels as well as copy number variations of HRH4 in a relatively
larger number of GC samples.
Most of the aCGH experiments focused on the genome-wide
screening of copy number variations (CNVs) and the data
obtained are generally informative but not definitive. Thus, a
study comprehensively examining CNVs in relation to HRH4
expression or prognosis should be performed using a large number
of tumors. In this study, our approach was based on real-time PCR
analysis, an established quantitative method examining the copy
number and expression level of the targeted gene [23,24].
Fluorescence in situ hybridization method was used to confirm
the copy number variations (CNVs) of the HRH4 gene in the
GCs. In addition, in vitro studies using GC cell line were carried out
to reveal the potential role of HRH4 abnormalities in the
progression of GC.
Materials and Methods
Patients and Tissue Collection
Gastric cancer samples were obtained from 131 surgical patients
of the Department of Gastroenterology, Shenzhen Hospital, Peking
University. A detailed description of patient characteristics was
included in (Table S1). The GC tissues were collected from patients
undergoing gastrectomy. Case-matched adjacent normal mucosa,
located at least 2 cm far from the macroscopically unaffected
margins of the tumor, were defined as normal controls. All the
samples were stored in liquid nitrogen immediately after the
operations. All 131 tumors were adenocarcinomas and other types
of tumors (squamous cell, carcinoid, and stromal tumors) were
excluded. Gastric carcinomas were staged according to the TNM
classification system and graded into 5 groups: Stage0 (TisN0M0,
n=0), Stage1 (T1N0–1M0, n=4), Stage2 (T1N2M0,T 2N0–1M0,
n=30), Stage3 (T2N2M0,T 3N1–2M0,T 4N0M0, n=54), Stage4
(T4N1–2M0,T 1–3N3M0,T anyNanyM1, n=43). The samples of
Stage0–1 were combined into Stage2 due to the small sample size.
Matched samples of GCs (n=131) and adjacent normal tissues
(ANTs, n=131) were immediately stored in liquid nitrogen after
operation.Foreachsample, a portion oftissuewasdisposedto make
frozen sections and then micro-dissected by the Eppendorf
Microdissection System (Siskiyou MX160L micromanipulator and
PixeLink PL-A662 color CCD firewire camera). Then the dissected
tissues were subjected to real-time PCR analysis. All patients were
informed about the aims of specimen collection and gave signed
written consent in accordance with the ethical guidelines of Peking
University. Peripheral blood samples from 152 healthy controls
were collected at Peking University People’s Hospital. The
investigations were conducted according to the Declaration of
Helsinki principles and the study was approved by the ethical
committee of Peking University Shenzhen Hospital.
Western blotting
Tissue samples (after freezing and grinding) or cells were washed
with PBS and lysed in a buffer containing 50 mM Tris-HCl
(pH 6.8), 2% SDS, 10% glycerol, phosphatase inhibitors (100 mM
Na3VO4, 10 mM NaF) and protease inhibitor (1 mM PMSF).
Equal amounts of protein were loaded on a SDS–PAGE and
transferred to PVDF membrane. After blocking with 5% non-fat
milk in TBS-T (containing 0.1% Tween-20), the membranes were
incubated with specific primary antibodies, followed by HRP-
conjugated secondary antibodies. Proteins were visualized by
fluorography using an enhanced chemiluminescence system. Data
of the blotting were analyzed by the Total-Lab software (V2.01).
Anti-HRH4 antibody was purchased from Chemicon Interna-
tional (Millipore, USA Canada); anti-cyclin D1, anti-p21 and anti-
p27 antibodies were purchased from Cell Signaling Technology,
Inc. (USA); anti-CDK2 and anti-aTubulin antibodies were
purchased from Sigma-Aldrich Corporation (JPN).
RT-PCR and Real-time quantitative PCR
Total RNA was isolated using the Trizol system according to
the manufacturer’s guidelines. Oligo (dT) 18 primer and M-MLV
reverse transcriptase were used for first strand synthesis. The
cDNA was then used as a template for real-time PCR and RT-
PCR with gene specific primers. Real-time PCR was performed
with Real-time PCR Master Mix containing SYBR GREEN I and
hotstart Taq DNApolymerase. GAPDH was amplified as control.
The primers for HRH4 and GAPDH are: HRH4 (sense): 59-
GTG GTT AGC ATA GGT TAT AC-39, HRH4 (antisense): 9-
ATG CCA CTG CAC TCC TGC-9; hGAPDH (Sense): 59-
CAGCCTCAAGATCATCAGCA-39; hGAPDH (anti-sense):59-
TGTGGTCATGAGTCCTTC CA-39 [24]. Real-time detection
of the emission intensity of SYBR GREEN bound to double-
stranded DNAs was performed using the I-cycler Instrument (Bio-
rad). At the end point of PCR cycles, melt curves were made to
check product purity. The level of H4R mRNA was expressed as a
ratio relative to the GAPDH mRNA in each sample.
Immunofluorescence staining
We selected a number of GC samples with significantly
attenuated HRH4 expression (according to results from Western
blot, n=15) to make paraffin-embedded tissue sections (4 mm
thick). Then the immunofluorescence staining was performed as
described previously [25]. The anti-HRH4- antibody (1:50,
CHEMICON, US) and the secondary antibody, conjugated with
CY3, (Jackson Immuno Research, US) were applied in the current
study.
DNA extraction and quantification of copy numbers
Genomic DNA was isolated from the tissues using the Genomic
DNA Extraction Kit (Innocent, Shenzhen, China) according to the
manufacturer’s instruction. The concentration of purified DNA
was determined by measuring the absorbance at 260 nm and
280 nm in a spectrophotometer. Pure preparations of DNA have
OD260/OD280.1.8. Quantitative PCR was performed through
BioRad Chromo4 real-time PCR system. The primers for RNAse
P are: forward: 59-AGA CTA GGG TCA GAA GCA A-39 and
reverse: 59-CAT TTC ACT GAA TCC GTT C-39.Two primer
sets for HRH4 gene are applied in this study: (1) forward: 59- GTG
GTT AGC ATA GGT TAT AC9 and reverse: 59- ATG CCA
CTG CAC TCC TGC -39 [24]; (2) forward: 59-CAG AGA TAG
GGC GAA GGA TT -39 and reverse: 59-TCC AAG CTC ACT
CAC CCT TA-39. PCR conditions for these reactions were: 95uC
5 min followed by 95uC3 0s ,5 7 uC2 5s ,7 2 uC 30 s (plate read) for
40cyles, then 72uC for 10 min.
Average copy numbers of RNAse P in normal candidates (copy
numbers=2) were used as control [24,26]. The copy numbers of
HRH4 were calculated by using the comparative Ct method. Each
Ct value was obtained from two independent reactions. Cut-off
values of 0.25, 0.75, 1.25, and 1.75 were used to define the copy
numbers as 0, 1, 2, and 3, respectively. Fold change of each sample
was presented as follows: fold change=relative expression level /
average expression level in the group with 2 copies of DNA. A
representative diagram for the DNA CNV analysis of the target
gene in three GC/ANT pair was shown in Figure S1.
A standard curve was prepared using 2 ml of crude DNA
solutions, in which serially diluted samples (original, 2-, 4-, 8-, 16-
diluted) were included. The slopes of Ct and efficiency of each
HRH4 Abnormalities in Gastric Carcinomas
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system and Microsoft Excel 2007 for Windows. Relative
quantification of HRH4 was performed with the 2
2DDCt method.
Fluorescence in situ hybridization (FISH) analysis
GC tissues and matched adjacent normal tissues were prepared
as introduced in the Materials and Methods. Ten N/T pairs (5
with HRH4 deletion, 5 with unaltered HRH4 copy number) were
selected for FISH analysis. For isolation of cells, 0.075 m KCl was
added to tissue for 10 min, and the tissue was minced with a
scalpel to form a suspension of single cells. The cell suspension was
fixed in methanol: acetic acid (3:1). The suspension of isolated
fixed nuclei was dropped on a slide and fixed by 70uC steam.
Target slides were denatured in 26SSC/70% formamide, pH 7,
at 75uC for 5 min and dehydrated in graded ethanol.
Dual labeling hybridization with 10 mlo fh y b r i d i z a t i o nm i x
and a directly labeled centromere probe specific for chromosome
18q (Spectrum Green-labeled) along with a Spectrum Orange-
labeled probe for the HRH4 locus (18q11) were performed.
Probes were denatured at 75uC for 5 min and applied to the
target slides. Hybridization was performed overnight at 37uC.
Post-hybridization washes were performed with 50% formamide/
26 SSC for 10 min three times, 26 SSC for 5 min, and 26
SSC/NP40 for 5 min at 45uC. Counterstaining was performed
with 49,6-diamino-2-phenylindole dihydrochloride. The number
of FISH signals was counted with an Olympus microscope
equipped with a triple band pass filter. A minimum of 300 nuclei
were evaluated. FISH signals were counted according to the
criteria described previously and were recorded as 0, 1, 2, 3, 4, 5,
or more signals for each probe.
Cells and culture conditions
The human gastric cancer cell lines (including AGS, MGC803,
BGC823, HGC-27, SGC7901 and MKN-45) were obtained from
the Department of Biochemistry, Hong Kong University of
Science and Technology. The AGS line, whose characteristics of
which are described in detail elsewhere [27,28], were propagated
in Dulbecco’s modified Eagle’s medium (DMEM, Gibco),
supplemented with 10% fetal bovine serum (PAA) and 1%
penicillin/streptomycin (Life Technologies, Inc.).
Plasmids and transfection
We used a previously described [17] expression construct
encoding HRH4 cDNA fragment (named pcDNA3-HRH4). To
produce stable transfectants, pcDNA3, pcDNA-HRH4 plasmids
were stably transfected to AGS line using Lipofectamine 2000
reagent (LF2000, Invitrogen, Carlsbad, CA) according to the
manufacturer’s recommendations. Selection was performed via
the addition of 1.2 mg/ml G418. The transfectants from
backbone vector and pcDNA3-HRH4 were designated as Mock-
AGS and H4R-AGS, respectively
Cell Proliferation and Cologenic Assay
Cell proliferation was measured by WST-1 assay. Mock-AGS
and H4R-AGS cells were plated in 96-well culture plates (1610
4
per well) and treated with or without histamine (10
25 M). WST-1
(Roche) assay measuring the activity of mitochondrial dehydroge-
nases was performed following the manufacturer’s instruction at
0-, 1-, 2-, 3- ,4- ,5- day time points.
To determine long-term effects, cologenic assay was used to
elucidate the possible differences in long-term effects of altered
HRH4 expression on human gastric cancer cells. Mock-AGS and
H4R-AGS cells were trypsinized and counted using a hemocy-
tometer. Cells (2610
4) were plated in the 6-well dishes and
supplemented with histamine or clobenpropit 24 h later. Two
weeks after the onset of drug selection, the cells were fixed and
stained with crystal violet (0.1% crystal violet in 20% methanol). A
cluster of a minimum of 50 cells is considered a colony.
Flow cytometric analysis of cell cycle
For cell-cycle assay, cells were trypsinized with 2 mM EDTA in
PBS and rinsed twice with ice-cold PBS solution, then fixed by
adding them drop-wise into 75% ice-cold ethanol while vortexing,
followed by incubation in ice for 60 min. The fixed cells were
washed with ice-cold PBS and incubated at 37uC for 30 min in
0.5 ml PBS solution containing 20 mg/ml RNaseA, 0.2% Triton
X-100, 0.2 mM EDTA and 20 mg/ml of propidium iodide. The
percentage of cells in G0/G1, S, and G2/M phases was
determined using the EPICS-XL flow cytometer (Beckman-
Coulter, USA) and the Multicycler program.
Statistical analysis
Statistical analysis was performed with the SPSS Software
(version 12). Data of HRH4 copy number were analyzed by the
chi-square test or Fisher exact test. P-values less than 0.05 were
considered statistically significant. Results of the H4R mRNA
expression for normal and tumor tissue samples were compared
using two-way repeated measurement ANOVA. One-way,
repeated measures analysis of variance (ANOVA-RM) was
performed at a significance level of p=0.05 to determine
differences from controls within each group. Two-way analysis
of variance (ANOVA-2) was performed after baseline subtraction,
at a significance level of p=0.05, to determine differences between
the groups with deleted and unaltered HRH4 copy number.
Statistical analysis of the results from flow cytrometry and colony
forming assay were done with t-test, with statistical significance set
at P,0.05.
Results
Attenuated expression levels HRH4 were observed in
gastric adenocarcinomas and were correlated with tumor
progression
We first examined the expression levels of H4R in the collected
GC samples. As shown in Figure 1A, attenuated expression levels
of the HRH4 protein were mainly observed in advanced GC
samples compared to matched adjacent normal tissues (ANTs).
Then we assessed the HRH4 mRNA expression in each T/N
pair using quantitative PCR method. It was found that mRNA
levels of HRH4 were reduced in the GC samples compared to
ANTs (Figure 1B). There was a statistical difference between the
group of early-stage GCs and advanced GCs. Figure 1C showed
the representative immunocytochemistry analysis of HRH4
expression in selected GC samples. The obtained results were in
accordance with the data from the immunoblottings.
Copy number loss of HRH4 gene contributes to the gene
repression in GCs
Little is known about the regulation of HRH4 expression. Since
no detectable CpG island was found on the proximal region of
HRH4 promoter (2 kbp, Figure S2), DNA methylation might not
play an important role in this progress. DNA deletion at
chromosome position 18q11, also the chromosome locus that
HRH4 gene resides, is frequent in gastrointestinal cancers [20,22].
We wondered if copy number variations (CNVs) of HRH4 gene
might play a role in the regulation of gene expression.
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pair as well as in healthy normal controls (HNCs). No statistical
differences of copy number distribution between adjacent normal
tissues (ANTs) and healthy normal controls were observed
(Table 1). Thus, the ANT could be used as controls for the GC
tissues in each N/T pair. As shown in Table 2, deletion of HRH4
gene was observed in a certain percentage (17.6%, 23 out of 131)
of collected GC samples. Much higher frequency of HRH4 gene
deletion was observed in the advanced GCs (21.6% for stage3–4)
than those in early-stage GCs (5.88% for stage0–2).
It is expected that the CNVs do have genotype-phenotype
correlation. Next, we selected the samples with either decreased or
unaltered copies of HRH4 and tested whether the HRH4 mRNA
expression was correlated with the copy numbers. As shown in
Figure 1. Decreased H4R expression in GCs. (A) Representative blots of HRH4 expression in normal mucosa and gastric tumor tissues. a-tubulin
was used as a stable endogenous control. (B) The histogram shows the anlysis of the results from the immunoblottings. The relative expression value
of HRH4 protein (normalized by a-tubulin) in GCs is expressed as an average ratio6s.e. of tumor dose to matched adjacent normal tissue dose.
*p,0.01 vs. Control, ANT. (C) Real-time PCR assay was carried out as described under Materials and Methods section, boxplots of relative HRH4
mRNA(HRH4/GAPDH) measured with real-time PCR analysis showing median; box: 25th–75th percentile; bars: largest and smallest values within 1.5
box lengths; little cross: outliers. The results were obtained from 3 reactions in each sample. (D) Representative immunofluorescent microscope
analysis of paired samples of GC tissue and adjacent normal tissue using anti human HRH4 monoclonal antibody (red). Nuclei were stain with DAPI
(blue). Sample I: gastric cancer (GC); sample II: adjacent normal control (ANT). Arrows point to region of positive staining.
doi:10.1371/journal.pone.0031207.g001
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HRH4 was significantly lower than those with unaltered copies
(p=0.000109). Thus, the copy number loss of HRH4 at least plays
a role in the down-regulation of HRH4 expression in GCs. On the
other hand, the reduced HRH4 expression was also observed in
the GC samples with unaltered copies, which indicated that there
are other mechanisms involved as well.
To confirm the CNVs of HRH4 gene in GCs, fluorescence in
situ hybridization analysis of chromosome 18q and 18q11 specific
probe (HRH4) were also performed in selected paraffin-embedded
GC tissues and matched ANT tissues (n=10, 5 deletion, 5
unaltered). The results obtained were in accordance with those
from real-time PCR analysis (Figure 2B and Table 3).
Alteration of HRH4 expression influences histamine-
mediated cell growth in gastric cancer cells
To investigate the role of impaired HRH4 expression in gastric
cancer, in vitro experiments using gastric cell lines were performed.
We first assessed the expression of HRH4 in several gastric cancer
cell lines (Figure S3). The AGS line with relatively lower
expression of H4R was selected. FISH approaches revealed the
loss of heterozygosity (LOH) of HRH4 gene in this cell line (Figure
S4).
H4R has been indicated to be involved in cell growth control in
different types of cells [12,13,14]. We wondered whether altered
expression of H4R could influence the proliferational ability of the
GC cells from exposure to histamine. We used histamine (HA), the
natural ligand of H4R, and clobenpropit (CB), one of the most
specific agonist of H4R, to activate H4R. Although CB is capable
of activating both H3R and H4R, it is an HRH4-specific agonist
here because gastric epithelium seldom express H3R [15]. As
shown in Figure 3A, both histamine and CB inhibited proliferation
of H4R-AGS cells at an optimal dose of 10
25 M, as illustrated by
the accumulation of cells in stage G0/G1 and decrease in G2/S,
while CB treatment has little influence on Mock-AGS cells.
Moreover, pre-treatment with the selective HRH4 antagonist
JNJ7777120 before exposure to histamine or CB prevented the
cell cycle arrest, providing additional evidence of the involvement
of H4R in the regulation of cell cycle.
To evaluate the long-term tumor growth influenced by
alteration of H4R expression, we performed the colony-forming
assay. As shown in Figure 3B, cells transfected with the HRH4
gene generated a lower number of colonies than those transfected
with the backbone vector after histamine treatment. Moreover, we
analyzed the growth potential of H4R-AGS cells by WST-1 assay
at different times after plating. The H4R-AGS cells grew at a
significantly slower rate when incubated with medium containing
histamine, while growth of Mock-AGS cells was not influenced by
the natural ligand of H4R (Figure 3C).
Effects of HRH4 activation on cell-cycle regulatory
molecules in GC cells
The CB-induced G1 arrest was further confirmed by examining
the cellular levels of the G1 cell-cycle control proteins cyclin D1
and Cdk2 in H4R-AGS cells. After H4R-AGS cells were treated
with 10
25 M CB or HA, the expression levels of cyclin D1 and
Cdk2 were attenuated while the expression levels of p21
Cip1 and
p27
Kip1 were substantially up-regulated stimulated by CB after
24 h. (Fig. 4A). Based on these findings, CB-mediated activation of
HRH4 is likely to block the cell-cycle progression through G1 to S
Table 1. Comparison of CNVs of HRH4 gene between adjacent normal tissues (ANT) and healthy normal controls (HNC) * from
peripheral blood.
Samples Copy number
n Deletion Amplification p (vs. HNC)
01 23.3
HNC 152 1 3 144 4 0 ---
ANT 131 3 4 121 2 1 0.989
*ANT represents adjacent normal tissues; HNC represents healthy normal controls
doi:10.1371/journal.pone.0031207.t001
Table 2. CNVs of HRH4 in GC tissues and matched adjacent normal tissues (ANTs).
Copy numbers P (vs. ANT) P (vs. Stage0-2)
CNVs, population n Deletion
2 ,2
Total ANT 131 127 4 --- ---
GC 108 23 1.13E-04 ---
Stage0-2 ANT 34 33 1 --- ---
GC 32 2 5.54E-01 ---
Stage3 ANT 54 52 2 --- ---
GC 44 10 1.09E-02 9.25E-2
Stage4 ANT 43 42 1 --- ---
doi:10.1371/journal.pone.0031207.t002
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not significantly influenced by CB or histamine treatment, which
further confirmed the role of HRH4 in this progress.
Discussion
The distribution of H1R, H2R and H4R in the epithelium of
gastrointestinal tissue has been indicated [15]. The relevance of
HRH4 abnormalities in colorectal cancer has been reported by
different groups [16,17]. In the current study, we first showed that
abnormalities of H4R were also present in GC tissues, which was a
novel finding. In colorectal cancers, expression levels of HRH4
mRNA were reduced regardless of the grade or Dukes
classification of the tumors [16,17]. In gastric malignancies,
however, attenuated H4R expression was mainly observed in
advanced GCs, which suggested that deletion and down-
regulation of HRH4 might mainly take place in the progression
but not the initiation of GCs.
The involvement of copy number variation (CNV) in the
regulation of HRH4 expression in GCs was also a novel finding.
Chromosomal aberrations such as deletions, amplifications, and
structural rearrangements are hall markers of somatic cancer and
lead to DNA copy number alterations with associated gain or loss
of genes important for tumor progression. CNVs identified by
CGH and array technology have been clearly shown to have the
potential to directly or indirectly influence a healthy individual’s
susceptibility to cancer, for example by varying the gene dosage of
tumor suppressors or oncogenes [29]. However, there are many
discrepancies among previous studies which used high-resolution
aCGH approaches to screen CNV. In the current study, the real-
time quantitative PCR method was applied to analyze the copy
number change in a relatively larger number of GC/ANT pairs,
Figure 2. Copy number loss of HRH4 in GCs. (A) Real-time PCR assay was carried out as described under Materials and Methods section, and the
results were obtained from indicated group of samples. Boxplots of relative copy number of HRH4 mRNA measured with Real-Time PCR analysis
showing median; box: 25th–75th percentile; bars: largest and smallest values within 1.5 box lengths; little cross: outliers. mRNA expression level of
HRH4 in groups with deleted (n=23) or unaltered (n=108) DNA copies. (B) Representative figure of FISH analysis using chromosome 18q specific
alpha satellite DNA probe and chromosome 18q11 specific probe for HRH4 gene. I. Nucleus of ANT tissue with two signals for each of green and
orange, showing no deletion of chromosome 18q or HRH4 gene. II. Nucleus of GC tissue with 0–2 signals for green and 0–2 signals for orange,
indicating relative deletion in chromosome 18q or HRH4 gene.
doi:10.1371/journal.pone.0031207.g002
Table 3. FISH results in 10 GC/ANT pairs.
Results from
Real-time PCR analysis
Case
number Stage GC ANT
HRH4 gene
deletion
Ratio (T/N)
Deletion of
18q11 (HRH4)
Deletion
of 18q
Deletion of
18q11 (HRH4)
Deletion
of 18q
Unaltered HRH4
gene copy number
1222 2 2 0.97
2322 2 2 1.03
3322 2 2 0.92
4322 2 2 1.15
5422 2 2 1.02
HRH4 gene deletion 6 2 + 22 2 0.39
73+ 22 + 0.71
84++ 22 0.44
94+ 22 2 0.67
10 4 ++ 22 0.19
doi:10.1371/journal.pone.0031207.t003
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Additional experiments using FISH analysis were also performed
to validate the obtained data. These helped to increase the
reliability of the results.
Since there were no statistical differences of CNVs of HRH4
between blood samples from healthy normal controls and adjacent
normal tissues from GC patients, the CNVs of HRH4 in GCs
were more likely acquired DNA aberrations. There was a
significant correlation between copy number deletion and down-
regulation of HRH4 gene in GCs, while the expression level of
HRH4 mRNA was also impaired in the group of GC samples with
unaltered copy numbers. Thus, there were different mechanisms
involved in the regulation of H4R expression in GCs, which
warrants further investigation.
In the histamine receptor family, HRH2 has long been known
to be important in both acid secretion and growth and
differentiation of the gastric mucosa [30]. Antagonist of H2R
could alter the proliferation level of gastric cancer [31,32]. As for
HRH4, no functional elucidation in gastric enterocytes has been
described. In this study, the results from the in vitro approaches
using GC cell line suggested that HRH4 stimulation could cause
cell growth arrest through the induction of the cyclin-dependent
kinase inhibitors, including p21
Cip1 and p27
Kip1. p21
Cip1 and
p27
Kip1 play important roles in mediating growth arrest and are
Figure 3. HRH4 activation induced growth arrest in gastric carcinoma cell lines. (A) Mock-AGS and H4R-AGS cells were treated with 10
25 M
histamine, CB or CB accompanied by HRH4 antagonist (JNJ7777120) pretreatment, and cell-cycle distributions were determined by propidium iodide
flow cytometry analysis. Each value is the mean6s.e. of triplicate data representative for three independent experiments. *p,0.05 and **p,0.01 vs.
Control, H4R-AGS cells without any treatment. (B) Colony-formation assay. 5610
3 Mock-AGS and H4R-AGS cells were treated as in Fig. 3A and
maintained in G418 for 14 days, and the colonies were stained with Giemsa. The bar graph shows the absolute colony ($50 cells) number6s.e. in
duplicate experiments. *p,0.05 and **p,0.01 vs. Control, H4R-AGS cells without any treatment. (C) Mock-AGS and H4R-AGS cells were treated as in
Fig. 3A, WST-1 (Roche) assay measuring the activity of mitochondrial dehydrogenases was performed following the manufacturer’s instruction at 0-,
1-, 2-, 3- ,4- ,5- day time points. Each value is the means.e. of triplicate data representative for three independent experiments. Error bars represent
standard deviation of the mean.
doi:10.1371/journal.pone.0031207.g003
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in p21
Cip1 and p27
Kip1 could, by inhibiting cyclin D1/Cdk4 or
Cdk6 kinase activity, explain, at least partially, the increase of cells
in the G1 phase by CB treatment in our study.
Overall, our results first revealed the presence of the
abnormalities of HRH4 in GCs and suggested its potential role
in histamine-mediated regulation of tumor growth. However, the
in vivo study underlying mechanisms of the HRH4 expression
levels, using HRH4-knockout mice, needs to be investigated in the
future.
Supporting Information
Figure S1 The representative diagram of the DNA CNV
analysis for oneT/N pair. (A) Real-time PCR amplification of
targeted gene in selected genomic DNA samples. Each data was
obtained from two independent reactions. (B) Original Ct values
obtained from the real-time PCR amplification. (C&D) The
efficiency of and slope of the RNAse P and HRH4 amplification
were calculated by Bio-Rad Thermal Cyclers software. The
detailed calculation was performed as follow: dCt=average Ct
(HRH4)-average Ct (RNAse P); ddCt (sample1)=dCt (GC)2dCT
(ANT)=2.96; Etarget was determined by the efficiency of target
gene amplification. Cut-off value (sample1)=E
2ddCt=2.05
22.96
=0.12. The copy number of HRH4 in sample1 is 0.
(TIF)
Figure S2 Prediction of potential CpG islands on the
promoter of HRH4 gene (GC rate.0.6) using online
tools.
(TIF)
Figure S3 Protein levels of HRH4 in the gastric cancer
cell lines were examined using Western blot assay, and
normalized with the amount of. Shown is representative
example of multiple experiments.
(TIF)
Figure S4 FISH analysis using chromosome 18q specific
alpha satellite DNA probe and chromosome 18q11
specific probe for HRH4 gene in AGS cells.
(TIF)
Table S1 Detailed description of Patient Characteris-
tics in this study.
(DOC)
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